IBEX 35
11.100,50 +68,20 (+0,62%) Euro Stoxx 50
4.942,06 +34,76 (+0,71%) Dólar/Euro
1,0742 +0,0045 (+0,42%) Petróleo Brent
85,38 +0,14 (+0,16%) Oro
2.344,60 +13,40 (+0,57%) Bitcoin EUR
57.113,89 -2.719,22 (-4,54%)
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
Guangdong Hybribio Biotech Co.,Ltd.
D5-3-3-4, North High-tech Zone
Chaozhou Economic Development Experimental Zone
Chaozhou 521000
China
86 76 8285 2923
https://www.hybribio.cn
Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 2669
Descripción
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.
Gobierno corporativo
El ISS Governance QualityScore de Guangdong Hybribio Biotech Co.,Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
